First-in-human feasibility study of the aXess graft (aXess-FIH): 6-Month results.

Matteo TozziJan De LetterDainis KrievinsJanis JushinskisAnnick D'HaeninckKestutis RucinskasMarius MiglinasTomas BaltrunasSigi NauwelaersAn S De VrieseFrans MollFrank Vermassen

Published in: The journal of vascular access (2024)

The expected advantages of the novel aXess Hemodialysis Graft over conventional AVGs would be evaluated by the analysis on long-term safety and effectiveness during the 5-year follow-up of the currently ongoing trial.

Keyphrases

endothelial cells
randomized controlled trial
systematic review
study protocol
clinical trial
peritoneal dialysis
chronic kidney disease
end stage renal disease
phase iii
induced pluripotent stem cells
phase ii
open label
double blind